论文信息 - Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. - 字舞流文

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Chih-Hsin Yang | F. de Marinis | J. Wolf | J. Vansteenkiste | F. Blackhall | J. Raats | O. Arrieta | M. Gottfried | P. Langmuir | R. Abratt | T. Milenkova | Valorie F. Chan | R. D. de Boer | J. Read | Chih‐Hsin Yang | Jessica Read